Shape Therapeutics has signed a multi-target strategic partnership and licence agreement with Roche to develop gene therapy for specific targets in Alzheimer’s disease, Parkinson’s disease, and rare disease areas. The deal means Shape is eligible to more than $3bn from Roche in initial and potential payments on meeting development, regulatory and sales milestones. Shape is also entitled to tiered royalty payments on future sales of products developed through the partnership. The preclinical activities to detect potential candidates will be conducted by Shape using its RNAfix and AAVid platforms.
For further information, see Pharmaceutical Technology (https://www.pharmaceutical-technology.com/news/roche-shape-gene-therapy-deal/)